Avai BioAVAI -6.27%24 EV-to-FCF is -19.43 as of Jun. 29, 2026. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,588 Software companies, Avai Bio ranks worse than 62972.23% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avai Bio's Enterprise Value is $22.28 Mil.
Avai Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.15 Mil. Therefore, Avai Bio's EV-to-FCF for today is -19.43.
The historical rank and industry rank for Avai Bio's EV-to-FCF or its related term are showing as below:
AVAI'
s EV-to-FCF Range Over the Past 10 Years
Min: -6585.83 Med: -63.27 Max: 4048.53
Current: -19.43
During the past 8 years, the highest EV-to-FCF of Avai Bio was 4048.53. The lowest was -6585.83. And the median was -63.27.
AVAI's EV-to-FCF is ranked worse than 100% of 1588
companies
in the Software industry
Industry Median: 13.98
vs AVAI: -19.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avai Bio's share price for today is $0.15.
Avai Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avai Bio EV-to-FCF Related Terms
Avai Bio EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Avai Bio's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Application subindustry, Avai Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio EV-to-FCF vs Software Industry
For the Software industry and Technology sector, Avai Bio's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avai Bio's EV-to-FCF falls into.
Avai Bio's current Enterprise Value is $22.28 Mil.
Avai Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a EV-to-FCF of -19.43 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #999999 out of 1588 companies in the Software industry.
Is Avai Bio's EV-to-FCF too high?
Avai Bio's current EV-to-FCF is -19.43. Based on the distribution chart, Avai Bio ranks #999999 out of 1588 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's EV-to-FCF compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #999999 out of 1588 companies for EV-to-FCF. This places Avai Bio in the lower half of its industry. The industry median EV-to-FCF is 13.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Software company?
The median EV-to-FCF among Software companies is 13.98, based on 1,588 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avai Bio and its competitors. For the Software industry, the median EV-to-FCF is 13.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current EV-to-FCF is -19.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current EV-to-FCF of -19.43. The current EV-to-FCF is -19.43. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Avai Bio (AVAI), the current EV-to-FCF is -19.43 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
